|1.||Davidson, Nicholas O: 5 articles (06/2009 - 01/2002)|
|2.||Malim, Michael H: 3 articles (12/2011 - 11/2003)|
|3.||Kennedy, Susan: 3 articles (06/2009 - 01/2002)|
|4.||Anant, Shrikant: 3 articles (10/2004 - 01/2002)|
|5.||Mukhopadhyay, Debnath: 3 articles (10/2004 - 01/2002)|
|6.||Mori, Seiichiro: 2 articles (10/2015 - 02/2015)|
|7.||Kukimoto, Iwao: 2 articles (10/2015 - 02/2015)|
|8.||Wakae, Kousho: 2 articles (10/2015 - 02/2015)|
|9.||Muramatsu, Masamichi: 2 articles (10/2015 - 02/2015)|
|10.||Xie, Aris: 2 articles (07/2015 - 01/2010)|
02/01/2013 - "Some of the best characterized restriction factors for HIV-1 are Tripartite Motif-5α (TRIM5α), preventing infection of nonhuman primates, although not being effective in humans, and apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC 3G), counteracted by the viral accessory protein Vif. "
01/28/2015 - "Pull-down experiments, immunoprecipitation assays and computational analyses were performed to analyze the interaction between Vif and microtubule-associated protein light chain 3B (LC3B), a major autophagy component, in presence or absence of the antiviral host factor apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), after HIV-1 infection or ectopic expression of Vif. "
01/01/2012 - "Mouse apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like editing complex 3 (mA3), an intracellular antiviral factor, has 2 allelic variations that are linked with different susceptibilities to beta- and gammaretrovirus infections among various mouse strains. "
02/25/2010 - "We have identified a post-entry CCR6-dependent mechanism of inhibition of HIV occurring at an early stage of infection mediated by the induction of the host restriction factor apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G). "
07/01/2008 - "To investigate the associations between polymorphisms of apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and different outcomes of HBV infection in the Chinese Han population. "
02/01/2002 - "Although initially promising, enthusiasm for apobec-1 gene therapy for hypercholesterolemia was blunted by the finding that uncontrolled transgenic expression of APOBEC-1 led to nonspecific editing of mRNAs and pathology. "
05/20/1996 - "Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits."
07/01/1999 - "We used this physiologic hypercholesterolemia model to study the effect of adenovirus-mediated hepatic gene transfer of rat apolipoprotein B mRNA editing enzyme (Apobec1) on modulation of plasma cholesterol levels. "
05/01/1998 - "In contrast, in apoE-/- mice, inactivation of apobec-1 caused a massive increase (from <0.5 to 55.5+/-16.4 mg/dL) in plasma apoB-100 concentration but an approximately 55% reduction in hypercholesterolemia due to partial amelioration of the marked VLDL+IDL elevation. "
|4.||Hepatocellular Carcinoma (Hepatoma)
06/01/1998 - "However, high-level expression of APOBEC-1 in transgenic mouse and rabbit livers causes liver dysplasia and hepatocellular carcinoma. "
04/01/1998 - "In comparison, over-expression of APOBEC-1 in HepG2 (HepG2-APOBEC) human hepatoma cells, induced promiscuous editing primarily 5' of the mooring sequence, but sites 3' of the C6666 were also used more efficiently. "
10/10/1999 - "This report quantifies for the first time the effect of altering APOBEC-1 protein abundance on the proportion of edited apoB mRNAs using transfected McArdle rat hepatoma cells which had been sorted by flow cytometry into populations expressing different levels of green fluorescent protein-APOBEC-1 chimera, GFP-APOBEC. "
11/25/1997 - "To test this hypothesis, the subcellular distribution of hemagglutinin- (HA) tagged APOBEC-1 expressed in transiently transfected hepatoma cells was determined by indirect immunofluorescence microscopy. "
03/01/2015 - "To realize the role of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B (APOBEC3B) in hepatocellular carcinoma (HCC) occurrence, mRNAs of APOBEC3B from tumor and non-tumor tissues of patients with hepatectomy were isolated and in vitro studies were designed. "
06/01/1998 - "These results indicates that long-term hepatic expression of APOBEC-1 at low levels sufficient to eliminate LDL does not cause apparent liver damage or liver tumors in transgenic mice. "
11/01/1998 - "We have examined apobec-1 gene expression in human gastrointestinal tumors and in colon cancer-derived cell lines. "
12/01/2014 - "This major expansion of cancer mutation data sets has provided unprecedented statistical power for the analysis of mutation spectra, which has confirmed several classical sources of mutation in cancer, highlighted new prominent mutation sources (such as apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) enzymes) and empowered the search for cancer drivers. "
09/15/2007 - "Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice."
07/09/1996 - "The recent observations of tumor formation in Apobec-1 transgenic animals, together with the fact that Apobec-1 is expressed in numerous tissues lacking apo-B, raises the issue of whether this enzyme is essential for a variety of posttranscriptional editing events. "
|1.||LDL Receptors (LDL Receptor)
|2.||Proteins (Proteins, Gene)
|8.||Messenger RNA (mRNA)
|9.||Apolipoproteins B (ApoB)
|10.||apolipoprotein B mRNA editing enzyme